A detailed history of Jpmorgan Chase & CO transactions in Wave Life Sciences Ltd. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 375,667 shares of WVE stock, worth $5.04 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
375,667
Previous 392,049 4.18%
Holding current value
$5.04 Million
Previous $1.96 Million 57.46%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

SELL
$5.12 - $9.01 $83,875 - $147,601
-16,382 Reduced 4.18%
375,667 $3.08 Million
Q2 2024

Aug 12, 2024

SELL
$4.38 - $6.48 $279,277 - $413,177
-63,762 Reduced 13.99%
392,049 $1.96 Million
Q1 2024

May 10, 2024

SELL
$3.54 - $6.84 $24,447 - $47,237
-6,906 Reduced 1.49%
455,811 $2.81 Million
Q4 2023

Feb 12, 2024

BUY
$4.16 - $6.87 $8,960 - $14,797
2,154 Added 0.47%
462,717 $2.34 Million
Q3 2023

Nov 14, 2023

SELL
$3.56 - $5.75 $54,062 - $87,319
-15,186 Reduced 3.19%
460,563 $2.65 Million
Q2 2023

Aug 11, 2023

BUY
$3.51 - $4.69 $128,943 - $172,291
36,736 Added 8.37%
475,749 $1.73 Million
Q1 2023

May 11, 2023

SELL
$3.58 - $6.3 $8,015 - $14,105
-2,239 Reduced 0.51%
439,013 $1.9 Million
Q4 2022

Feb 13, 2023

SELL
$3.18 - $7.0 $11,502 - $25,319
-3,617 Reduced 0.81%
441,252 $3.09 Million
Q3 2022

Nov 14, 2022

SELL
$2.37 - $4.28 $76,411 - $137,991
-32,241 Reduced 6.76%
444,869 $1.61 Million
Q2 2022

Aug 11, 2022

SELL
$1.23 - $3.25 $495,109 - $1.31 Million
-402,528 Reduced 45.76%
477,110 $1.55 Million
Q1 2022

May 11, 2022

SELL
$2.0 - $3.28 $121,006 - $198,449
-60,503 Reduced 6.44%
879,638 $1.76 Million
Q4 2021

Feb 10, 2022

SELL
$3.14 - $5.15 $235,518 - $386,280
-75,006 Reduced 7.39%
940,141 $2.95 Million
Q3 2021

Nov 12, 2021

BUY
$4.89 - $7.12 $4.96 Million - $7.23 Million
1,015,147 New
1,015,147 $4.97 Million

Others Institutions Holding WVE

About Wave Life Sciences Ltd.


  • Ticker WVE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 86,820,096
  • Market Cap $1.16B
  • Description
  • Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional pr...
More about WVE
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.